Angiotensin-converting Enzyme (ACE)

血管紧张素转换酶 (ACE) 通过使血管收缩间接增加血压。ACE 通过将血管紧张素 I 转化为血管紧张素 II(使血管收缩)来实现这一点。ACE、血管紧张素 I 和血管紧张素 II 都是肾素-血管紧张素系统 (RAS) 的一部分,该系统通过调节体液量来控制血压。ACE 由血管内皮细胞(内层)分泌到肺和肾中。它具有两个主要功能:ACE 以底物浓度依赖性方式催化血管紧张素 I 转化为血管紧张素 II(一种强效血管收缩剂)。ACE 会降解缓激肽(一种强效血管扩张剂)和其他血管活性肽。这两种作用使 ACE 抑制成为治疗高血压、心力衰竭、糖尿病肾病和 2 型糖尿病等疾病的目标。抑制 ACE(通过 ACE 抑制剂)会导致血管紧张素 II 的生成减少和缓激肽的代谢减少,从而导致动脉和静脉系统性扩张以及动脉血压降低。

Angiotensin-converting enzyme (ACE) indirectly increases blood pressure by causing blood vessels to constrict. ACE does that by converting angiotensin I to angiotensin II, which constricts the vessels. ACE, angiotensin I and angiotensin II are part of the renin-angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body. ACE is secreted in the lungs and kidneys by cells in the endothelium (inner layer) of blood vessels. It has two primary functions: ACE catalyses the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor in a substrate concentration-dependent manner. ACE degrades bradykinin, a potent vasodilator, and other vasoactive peptides. These two actions make ACE inhibition a goal in the treatment of conditions such as high blood pressure, heart failure, diabetic nephropathy, and type 2 diabetes mellitus. Inhibition of ACE (by ACE inhibitors) results in the decreased formation of angiotensin II and decreased metabolism of bradykinin, leading to systematic dilation of the arteries and veins and a decrease in arterial blood pressure.

共 1种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
ME3221

ME3221 是一种血管紧张素 AT1 受体拮抗剂,可有效拮抗大鼠和狨猴对血管紧张素 II 的升压反应,而不影响对缓激肽的降压反应,并在肾性高血压大鼠和自发性高血压大鼠 (SHR) 中表现出强大的抗高血压作用,且在 SHR 中重复给药可产生持续稳定的降压效果而不影响心率,表明其具有研究肾性和原发性高血压的潜力。

139958-16-0
Antagonist
ME3221

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础